AVROBIO, Inc. (AVRO) Financials

AVRO Assets vs Liabilities

DateAssetsLiabilities
Dec. 31, 2023 101.1 million 6.4 million
Sept. 30, 2023 110.5 million 7.7 million
June 30, 2023 133.8 million 11.8 million
March 31, 2023 83.0 million 30.0 million

AVRO Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2023 -8.0 million 607000
Sept. 30, 2023 -20.2 million 2.2 million
June 30, 2023 -14.7 million 1.5 million
March 31, 2023 -20.3 million 2.5 million

AVRO Net Income

No data available :(

AVRO Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2023 98.3 million - 878000
Sept. 30, 2023 105.8 million - 1.8 million
June 30, 2023 124.7 million - 2.4 million
March 31, 2023 72.3 million 15.4 million 3.0 million

AVRO Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2023 44.7 million
Sept. 30, 2023 44.5 million
June 30, 2023 44.3 million
March 31, 2023 44.0 million

AVRO Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2023 - 4.4 million 5.2 million -
Sept. 30, 2023 - 14.8 million 6.3 million -
June 30, 2023 - 11.1 million 4.6 million -
March 31, 2023 8000 17.3 million 7.9 million -

AVRO Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2023 - -
Sept. 30, 2023 - -
June 30, 2023 - 879000
March 31, 2023 - 920000

AVRO

Price: $1.40

52 week price:
0.88
1.65

Earnings Per Share: 0.69 USD

P/E Ratio: 2.20

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 362600

Market Capitalization: 68.2 million

Links: